Form 4 Filing for Valion Bio, Inc.

On June 18, 2026, Lisa G. Wolf, Chief Financial Officer of Valion Bio, Inc., reported transactions related to her holdings. Wolf acquired 92 shares of Common Stock under a transaction code "M" with no cost, increasing her direct ownership to 618 shares. Concurrently, she disposed of 92 Restricted Stock Units (RSUs), which are convertible into Common Stock on a one-to-one basis. These RSUs vested in installments, with 50% vesting on December 18, 2025, and the remainder vesting quarterly over the following two years. Post-disposal, Wolf directly owns 551 RSUs. Both transactions were marked as direct ownership and occurred on the same date.